|
Saturday, April 29
8:00am–11:00am
2100—Adult Stem Cells—A Primer for the
Clinician
PAS/ASPHO Mini Course
Room 3014, Moscone West
Chairs: Jakub Tolar, University of Minnesota, Minneapolis, MN; and
Mervin C. Yoder, Jr., Indiana University School of Medicine,
Indianapolis, IN
Target Audience:
Hematologists/oncologists, endocrinologists, basic scientists
and neurologists.
Adult stem cells represent a
technology that is being intensively investigated currently,
and this research may have wide implications for human health.
This mini course will focus on recent research and potential
applications in human health.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
Mervin C. Yoder, Indiana
University School of Medicine, Indianapolis, IN
-
Multipotent Adult Progenitor
Cell: Hype or Reality?
Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN
-
Mesenchymal Stem Cell: Harnessing
the Power of Adult Stem Cells To Repair Tissues
Darwin Prockop, Tulane University Health Science Center, New Orleans,
LA
-
Hierarchy of Endothelial
Progenitors in Human Blood and Blood Vessels
David A. Ingram, Indiana University School of Medicine, Indianapolis,
IN
-
Cancer Stem Cell: Concept of
Human Leukemic Development
Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Sponsored jointly by
the American Society of Pediatric Hematology/Oncology and the
Pediatric Academic Societies
10:30am–12:30pm
2315—Brain Metabolism and Injury:
Mechanisms of Neuronal Injury and Neuroprotection
PAS Poster Symposium
Room 3024, Moscone West
Chairs: John D.E. Barks and Jeremy D. Marks
12:00pm–3:00pm
2505—Embryonic Stem Cells: A Primer for
Clinicians
PAS Mini Course
Room 3014, Moscone West
Chair: Michael T. Longaker, Stanford University, Stanford, CA
Embryonic stem cells offer
incredible promise for treating diseases affecting both
children and adults. This mini course will provide an overview
of stem cells and a basic understanding of how to derive human
embryonic stem cells, recent research and ethical
considerations. After attending this session, attendee will
have a better understanding of: 1) what are embryonic stem
cells; 2) how human embryonic stem cells are derived; 3)
recent progress in human embryonic stem cell research; 4)
ethical considerations in human embryonic stem cells.
-
Stem Cells: Embryonic, Adult and
Cancer
Michael T. Longaker, Stanford University, Stanford, CA
-
What It Takes Clinically To Get
an Embryonic Stem Cell
Linda C. Giudice, University of California, San Francisco, San
Francisco, CA
-
What Can You Do with an Embryonic
Stem Cell in Research
Renee Reijo Pera, University of California, San Francisco, San
Francisco, CA
-
Ethical and Oversight
Considerations in Human Embryonic Stem Cell Research
Hank Greely, Stanford University, Stanford, CA
-
Panel Discussion
Supported in part by an unrestricted educational grant from
Treuman Katz Center for Pediatric Bioethics - Seattle
Children's Hospital
12:00pm–3:00pm
2510—Inherited Disorders Caused by
Inappropriate Apoptosis
PAS Mini Course
Room 3010, Moscone West
Chairs: Cynthia J. Tifft, Children's National Medical Center,
Washington, DC; and Hans Andersson, Tulane University Medical
Center, New Orleans, LA
Target Audience: Pediatric
researchers interested in genetic basis of disease and
apoptosis.
This session will describe the
recent findings of the role of apoptosis in the pathogenesis
of genetic diseases. Inappropriate apoptosis and acquired
resistance to apoptosis are important mechanisms in some
genetic disorders and a better understanding of this role is
expected to lead to potential therapies.
Inappropriate apoptosis has been
implicated in the causation of several inherited disorders
with specific interest for pediatricians. The pathophysiology
of inherited neurodegenerative disorders have long eluded
explanation and recent studies suggest that storage of
abnormal compounds in lysosomes act as a trigger for
apoptosis. Additionally, nephropathic cystinosis has recently
been shown to be caused by inappropriate onset of apoptosis
caused by abnormal cystinylation. This session will provide a
clinical perspective on the role of apoptosis in genetic
disorders affecting the pediatric population.
-
Overview
Hans C. Andersson, Tulane University Medical School, New Orleans, LA
-
Microglial Activation and
Inflammation Precedes Apoptosis in Tay-Sachs Disease
Cynthia J. Tifft, Children's National Medical Center, Washington, DC
-
Lysosomal Cystine Enhances
Apoptosis and Yields the Nephropathic Cystinotic Phenotype
Jess G. Thoene, Tulane University School of Medicine, New Orleans, LA
-
Niemann Pick Disease, Type C:
Glycolipid Gridlock and Apoptosis
Marc C. Patterson, Columbia University Medical Center, New York, NY
- Role of GM1-Ganglioside
in ER-and Mitochondrial-Mediated Neuronal Apoptosis
Alessandra
D'Azzo, St. Jude Children’s Research Hospital, Memphis,
TN
-
Discussion
1:00pm–3:00pm
2630—Neurology
PAS Platform Session
Room 3020, Moscone West
Chairs: Anne M. Comi and Yvonne W. Wu
3:15pm–5:15pm
2720—Advances in Autism: One Step Forward
and One Step Back
PAS Topic Symposium
Room 3020, Moscone West
Chairs: Catherine E. Lord and Faye S. Silverstein, University of
Michigan, Ann Arbor, MI
Target Audience: Pediatricians
and other physicians and professionals who see children and
adolescents within their practices and researchers interested
in general summaries of the most recent advances in scientific
approaches to autism.
Dr. Lord is a developmental
psychologist with clinical and research expertise in the
diagnosis and treatment of autism spectrum disorders (ASD).
She chaired the National Academy of Science’s Early
Intervention in Autism Committee. She is best known for her
longitudinal studies of children and adults with autism and
the development of the standard autism diagnostic measures.
She has recruited a group of researchers with expertise
ranging from epidemiology to innovative clinical projects for
this symposium. The speakers will present recent findings and
discuss advances and controversies from a variety of fields
relevant to ASD and pediatrics. New prevalence studies from
the United States and other countries, epidemiological studies
of autism and vaccine use and current medical treatments will
be discussed, as well as practical ways of working with
parents interested in alternative therapies and skeptical
about conventional medicine. The role of early screening and
identification of ASD in infants and toddlers will be raised,
with particular attention to the ethics of research and
practice in this area. A summary of genetic findings will be
integrated with a discussion of methods of diagnosis and the
most recent empirically based studies of behavioral and
educational treatments.
-
Back from Diagnosis to Genetics;
Forward from Diagnosis to Behavioral and Educational
Programming
Catherine E. Lord, University of Michigan, Ann Arbor, MI
-
Screening and Early
Identification
Lonnie Zwaigenbaum, McMaster University, Hamilton, ON, Canada
-
Changes in Prevalence, Demands
for Treatment and What's a Pediatrician To Do?
Susan E. Levy, Children's Hospital of Philadelphia, Philadelphia, PA
-
Eating (and Not Eating) and
Sleeping (and Not Sleeping)
Susan Hyman, University of Rochester, Rochester, NY
-
Discussion
Sponsored jointly by
the Child Neurology Society and the Pediatric Academic
Societies
4:00pm–7:30pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
5:15pm–7:15pm
Poster Session I and PAS Opening Reception
PAS Poster Session
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
Includes:
-
SPR Student Research Award:
Resuscitation of Non-Viable Infants: Will
Neonatologists[apos] Practice Change After the Born-Alive
Infant Protection Act?
Mya Sendowski, University of California, San Francisco, CA
Sunday, April 30
7:00am–8:00am
3055—Child Neurology in the New Millennium
PAS Meet the Professor
Yerba Buena Gardens Salon 14, SF Marriott
Attendees will learn about
training in child neurology from the immediate Past-President
of the Child Neurology Society. Dr. Bale will provide an
overview of training and prerequisites, discuss the child
neurology match initiated in 2004 and describe plans for
integrated training in child neurology and pediatrics.
11:00am–4:00pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
12:00pm–1:30pm
3440A—Perinatal Brain Club
Hypothermia as a Neuroprotective Strategy in Term Infants
Club
Room 3022-3024, Moscone West
-
Introduction
Jeffrey M. Perlman, Weill Cornell Medical College, New York, NY
-
Hypothermia and Neuroprotection—Future
Strategies Based on Experimental Observations
Marianne Thoresen, University of Bristol, Bristol, England, UK
-
Hypothermia as a Neuroprotective
Strategy—Translating Science into Clinical Practice:
What Are the Hidden Obstacles?
Lu-Ann Papile, University of New Mexico Health Science Center,
Albuquerque, New Mexico
-
Discussion
Contact for information:
Jeff Perlman, MD
Weill Cornell Medical College
Phone: 212-746-3533
Email: jmp2007@med.cornell.edu
12:00pm–2:00pm
Poster Session II
PAS Poster Session
Levels 1 and 2, Moscone West
Posters Available for Viewing:
11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
Includes
-
SPR Fellow's Basic Research
Award: Myopalladin Mutations and Inherited
Cardiomyopathies
Enkhsaikhan Purevjav, Baylor College of Medicine, Houston, TX
-
SPR Clinical Research Award:
Accelerated Development in the Visual Areas of Preterm
Infants? A Voxel-Based Morphometry Study on Diffusion
Tensor MR Imaging (DTI)
Maria Miranda, Copenhagen University Hospital, Hvidovre, Denmark
-
SPR Fellow's Clinical Research
Award: Novel Genotyping Technology To Classify Childhood
Leukemia
Joshua D. Schiffman, Stanford University, Palo Alto, CA
-
SPR House Officer Research Award:
Erythropoietin Protein Expression in the Developing Human
Eye
Shrena Patel, University of New Mexico, Albuquerque, NM
2:00pm–4:00pm
3726—Neonatal Neurology: MRI and aEEG in
the NICU
PAS Poster Symposium
Room 3020, Moscone West
Chairs: Linda S. de Vries and Terrie E. Inder
4:15pm–5:45pm
3810—RNA Interference, Technological
Development of siRNAs and Potential Treatments for Childhood
Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School, Massachusetts
General Hospital, Boston, MA
Target Audience: Basic scientists
studying a broad range of childhood diseases, translational
scientists of all disciplines studying clinical implications
of basic science research, clinical scientists studying
childhood and other diseases in need of improved therapies and
clinicians interested in cutting-edge science and its medical
implications.
RNA interference is a recently
discovered, naturally occurring intracellular process that
regulates gene expression through the silencing of specific
mRNAs. Methods of harnessing this natural pathway are being
developed that allow the catalytic degradation of targeted
mRNAs using specifically designed complementary small
inhibitory RNAs (siRNA). siRNAs are being chemically modified
to acquire drug-like properties. Numerous recent high-profile
publications have provided proofs of concept that RNA
interference may be useful therapeutically. Much of the design
of these siRNAs can be accomplished bioinformatically, thus
potentially expediting drug discovery and opening new avenues
of therapy for many childhood diseases including uncommon
pediatric and orphan diseases. A discussion of the science
behind RNA interference will be followed by a presentation of
the potential practical issues in applying this technology to
disease. The program then describes two therapeutic programs
currently under way with applications to pediatric diseases. A
question-and-answer time will follow each discussion.
-
The Science of RNA Interference
John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA
-
RNA Interference and Its
Potential Applications for Controlling Disease
Judy Lieberman, CBR Institute for Biomedical Research and Harvard
Medical School, Boston, MA
-
Silencing the VEGF Pathway with
siRNAs and the Potential Application to Retinopathy of
Prematurity
Pamela Pavco, Sirna Therapeutics, Boulder, CO
-
siRNA as Therapy for Respiratory
Syncytial Virus
John P. DeVincenzo, University of Tennessee School of Medicine,
Memphis, TN
4:15pm–6:15pm
3865—Neonatal Neurology—Neural Stem Cells
and Neurotrophins
PAS Poster Symposium
Room 3020, Moscone West
Chairs: Sandra E. Juul and Patrick S. McQuillen
4:15pm–6:15pm
3870—Neonatal Public Health
PAS Poster Symposium
Room 3014, Moscone West
Chairs: Henrietta S. Bada and Robert A. Sinkin
Includes
-
Douglas K. Richardson Award for
Perinatal and Pediatric Healthcare Research
Marie C. McCormick, Harvard School of Public Health and Harvard Medical
School, Boston, MA
Monday, May 1
8:00am–10:00am
4105—MRI of the Brain in Neonates
PAS Topic Symposium
Room 3022-3024, Moscone West
Chairs: Terrie E. Inder and Jeff J. Neil, St. Louis Children's
Hospital, St. Louis, MO
Target Audience: Neonatologists,
neurologists, radiologists and trainees.
Magnetic resonance (MR) imaging
remains a rapidly evolving field, particularly in its
application to newborn infants. This symposium will first
review the basics of MR imaging methods (including
conventional and diffusion MR imaging) and then highlight
clinical applications of these methods to common neonatal
clinical conditions in the term and premature infant. The
talks will be targeted to clinicians and aimed to address key
clinical questions such as:
– In which infants should I
undertake an MR scan in my NICU?
– What are the strengths and weakness of MRI/CT/cranial
ultrasound?
– How can I undertake MR imaging in my institution—safety,
image sequences and interpretation?
– When should I undertake an MR scan in the term or
premature infant?
– What do the abnormalities in the MR scan mean for
long-term neurological outcome?
– How should I use this information in my clinical practice
in the NICU?
– Where is MR imaging taking us in the next 10 years in
newborn medicine?
-
A-B-C of M-R-I
Jeffrey J. Neil, Washington University and St. Louis Children's
Hospital, St. Louis, MO
-
Application of MR Imaging to the
Term Infant
Mary Rutherford, Hammersmith Hospital, London, UK
-
Application of MR Imaging to the
Preterm Infant
Terrie E. Inder, Washington University and St. Louis Children's
Hospital, St. Louis, MO
-
X-Y-Z- of M-R-I—The Future with
Advanced MR Methods
Petra S. Huppi, Children's Hospital, University of Geneva, Geneva,
Switzerland
8:00am–10:00am
4110—Pediatric Fluids and Hyponatremia: Are
We Giving Too Much Water?
PAS/ASPN/LWPES Topic Symposium
Room 3007-3011, Moscone West
Chairs: John W. Foreman, Duke University Medical Center, Durham, NC;
and D. Michael Foulds, University of Texas Health Science
Center at San Antonio, San Antonio, TX
Target Audience: Nephrologists,
general pediatricians, emergency room doctors, intensivists,
hospitalists, endocrinologists and anyone who administers IV
maintenance fluids.
In the 1950s, Holiday and Segar
devised formulae for calculating intravenous maintenance
fluids for infants and children who were unable to drink.
These formulae have been taught and used now for over 40 years
and have generally stood the test of time. However, several
recent investigators have challenged these formulae and argued
that they put children at risk of hyponatremia. Since Holiday
and Segar devised these formulae, new information has arisen,
such as the concept of non-osmotic stimulation of ADH release
in sick children and our ability to measure ADH levels in
plasma on a routine basis. Arieff and Ayus were the first to
point out that children and women are at particular risk for
developing hyponatremic encephalopathy. Moritz and Ayus have
subsequently argued that hypotonic parenteral fluid should not
be used unless there are ongoing free water losses or
hypernatremia. In addition to this new clinical data,
Verkman’s group has exciting data identifying molecular
mechanisms of cerebral edema, including after water
intoxication. Dr. Arieff will review who is at risk and why.
Dr. Verkman’s group has developed data regarding mechanisms
of cerebral edema in experimental animals. Dr. Moritz will
describe the new concepts of maintenance fluids. Dr. Friedman
will defend the current practice. At the end there will be
time for an exchange between the speakers and the audience on
the right fluid to use in today’s children.
-
Hyponatremic Encephalopathy:
Special Risk Factors for Children and Women
Allen I. Arieff, University of California San Francisco, San Francisco,
CA
-
Aquaporin 4 and Cerebral Edema
Alan S. Verkman, University of California San Francisco, San Francisco,
CA
-
0.9% Sodium Chloride: The New
Approach to Maintenance Fluids in Pediatrics
Michael L. Moritz, Children's Hospital of Pittsburgh, Pittsburgh, PA
-
Maintenance Therapy: Tried and
True
Aaron L. Friedman, Brown Medical School, Hasbro Children's Hospital,
Providence, RI
Sponsored jointly by
the AAP Section on Nephrology, the American Society of
Pediatric Nephrology, the Lawson Wilkins Pediatric Endocrine
Society and the Pediatric Academic Societies
8:15am–10:15am
4180A—Chronic Organ Damage in Sickle Cell
Disease: Diagnosis, Prevention and Treatment
ASPHO Symposium
Room 3016-3018, Moscone West
Chair: Russell E. Ware, St. Jude Children’s Hospital, Memphis, TN
Chronic organ damage is
increasingly recognized as an important source of morbidity
and mortality for young persons with sickle cell disease. This
symposium will include descriptions of several prospective
multicenter clinical trials that focus on the diagnosis,
treatment and prevention of organ damage in this common
hematological disorder.
After attending this session, it
is expected that the learner will be able to:
1. Discuss ongoing prospective
multicenter randomized clinical trials that focus on brain
damage in pediatric patients with sickle cell anemia.
2. Describe prospective clinical trials that focus on spleen
and kidney damage in very young patients with sickle cell
anemia.
3. Describe new imaging modalities for transfusional iron
overload in the liver and heart, as well as studies using new
oral iron chelating agents for its therapeutic management.
-
Introduction and Overview
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Brain
-
Silent Infarct Transfusion (SIT)
Trial
Michael R. DeBaun, Washington University School of Medicine, St. Louis,
MO
-
Stroke with Transfusions Changing
to Hydroxyurea (SWiTCH) Trial
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Spleen and Kidney
-
Splenic Function in Young
Children: Lessons from BABY HUG
Zora R. Rogers, The University of Texas Southwestern Medical Center,
Dallas, TX
-
Renal Function in Young Children:
BABY HUG, Toddler HUG
Sherri A. Zimmerman, Duke University Medical Center, Durham, NC
-
Liver and Heart
-
New Imaging Techniques for
Transfusional Iron Overload
Thomas D. Coates, Children's Hospital of Los Angeles, Los Angeles, CA
-
Oral Iron Chelators for the
Management of Transfusional Iron Overload
Alan R. Cohen, Children's Hospital of Philadelphia, Philadelphia, PA
-
Questions and Panel Discussion
10:15am–12:15pm
4350—Mechanisms of Brain Injury
PAS Poster Symposium
Room 3020, Moscone West
Chairs: Maria Delivoria-Papadopoulos and Jeffrey M. Perlman
10:15am–12:15pm
4355—Neurodevelopmental Outcomes of NICU
Graduates
PAS Poster Symposium
Room 3022-3024, Moscone West
Chairs: Scott A. Lorch and Michele C. Walsh
10:15am–12:15pm
4360—New Perspectives on ADHD
PAS Poster Symposium
Room 2002, Moscone West
Chairs: Marc A. Lerner and Mark L. Wolraich
3:00pm–5:00pm
4670—Brain Metabolism and Injury
PAS Platform Session
Room 3020, Moscone West
Chairs: Steven P. Miller and Frances J. Northington
Includes
-
SPR Fellow's Basic Research
Award: The Neuron-Glia Lactate Shuttle Protects
Neurological Function in Neuron-Specific Glucose
Deficiency
Camille Fung, David Geffen School of Medicine at UCLA, Los Angeles, CA
Tuesday, May 2
8:00am–10:00am
5105—Not All Near-Term Infants Are Born
Equal
PAS Topic Symposium
Room 3002-3008, Moscone West
Chairs: Lucky Jain, Emory University, Atlanta, GA; and Tonse N.K. Raju,
National Institute of Child Health and Human Development,
Rockville, MD
Target Audience: Neonatologists
and pediatricians.
Infants born at >34 weeks and
<38 weeks are often presumed to be mature and treated at
par with term infants. However, there is considerable
epidemiologic information to show that these infants have
considerably higher rates of NICU admissions and are at risk
for serious morbidity and death. Causes of morbidity include
delayed respiratory transition and surfactant deficiency,
hyperbilirubinemia, hypothermia, hypoglycemia and poor
initiation of feeding, etc. This symposium is designed to
review the physiological events related to neonatal transition
at birth and the pitfalls in the transition of a near-term
infant. The symposium should create awareness among
neonatologists and pediatricians for these morbidities and
suggest ways to overcome them.
-
Overview
Lucky Jain, Emory University, Atlanta, GA
-
Epidemiology and Overview of
Near-Term Births
Tonse N.K. Raju, National Institute of Child Health and Human
Development, Rockville, MD
-
Respiratory Transition and
Morbidity in Near-Term Infants
Lucky Jain, Emory University, Atlanta, GA
-
Brain Maturation and Pathology in
Near-Term Infants
Hannah Kinney, Harvard University, Boston, MA
-
Hyperbilirubinemia and
Kernicterus in Near-Term Infants
Vinod K. Bhutani, Stanford University School of Medicine, Stanford, CA
-
Post-Discharge Morbidity and
Rehospitalization in Near-Term Infants
Gabriel J. Escobar, Kaiser Permanente, Oakland, CA
-
Discussion
Supported by an unrestricted educational grant from INO
Therapeutics
8:00am–10:00am
5168—Oxidants, Antioxidants and the Battles
They Wage
PAS Poster Symposium
Room 3014, Moscone West
Chairs: Jonathan M. Davis and Charles V. Smith
10:15am–12:15pm
5425—A Spectrum of Neurodevelopmental
Disabilities
PAS Poster Symposium
Room 2006, Moscone West
Chairs: Bruce K. Shapiro and Robert G. Voigt
|
